3943. Fazadinium Bromide
Nomenclature
CAS number: 49564-56-9
1,1′-Azobis[3-methyl-2-phenylimidazo[1,2-a]pyridinium]
dibromide; AH-8165; Fazadon (Glaxo Wellcome). C28H24Br2N6; mol wt 604.34.
C 55.65%, H 4.00%, Br 26.44%, N 13.91%.
Description and references
A short-acting curarimimetic with rapid onset. Prepn: D. Jack, E. E. Glover, DE 2127355; eidem, US 3773746 (1971, 1973 both to Allen & Hanburys); E. E. Glover, M. Yorke, J. Chem. Soc. C 1971, 3280. Pharmacology: L. Bolger et al., Nature 238, 354 (1972); and toxicity data: P. Bellani et al., Farmaco Ed. Sci. 39, 846 (1984). Clinical pharmacokinetics: T. Busi et al., Minerva Anestesiol. 49, 485 (1983). Clinical use: G. Minutella, G. Bongiovanni, ibid. 301; A. Lusini et al., ibid. 393.
Derivative
Dihydrate.Properties
Yellow crystals from water, mp 215-219° (softens at 196°). Also reported as yellow solid from methanol/ethyl acetate, mp 218-220°. uv max (H2O): 285, 297 nm (log ε 4.04, 4.34). LD50 i.v. in rats: 1.5 μM/kg (Bellani).Therapeutic Category
Neuromuscular blocking agent.
Keywords
Neuromuscular Blocking Agent; Nondepolarizing Agents